Exeq BioForum 2012 presentation

31
Public funding opportunities for R&D and innovation projects Jan Kaczmarek, CSO, Partner – EXEQ

description

Exeq presentation of funding opportunities for the biotechnology sector

Transcript of Exeq BioForum 2012 presentation

Page 1: Exeq BioForum 2012 presentation

Public funding opportunities for R&D

and innovation projects

Jan Kaczmarek, CSO, Partner – EXEQ

Page 2: Exeq BioForum 2012 presentation

2Public funding for R&D&I

about us• grant consultancy• specilized in R&D and innovation programmes• 7 years in business• team of 10 consultants• domain experts (computer science,

telecommunications, biotech) from recognised R&D institutes

• ~20 projects annually• success rate: ~3 x average retention rate

Page 3: Exeq BioForum 2012 presentation

3Public funding for R&D&I

about me• Co-funder of EXEQ• R&D project manager, proposal writer, consortia

matchmaker (since 2004)• (co)authored over 50 proposals• ~ 10K working hours• Economics and IT background• Project evaluator (incl. 7th Framework Programme)

Page 4: Exeq BioForum 2012 presentation

4Public funding for R&D&I

customers

Page 5: Exeq BioForum 2012 presentation

5Public funding for R&D&I

EU-level programmes

Page 6: Exeq BioForum 2012 presentation

6Public funding for R&D&I

programmes in Poland

Technological Loans

R&D project for companies

1.4 3.3.2 5.4.1 6.1

8.1 8.2

2.1.1 6.1

Page 7: Exeq BioForum 2012 presentation

7Public funding for R&D&I

agenda• introduction• overview of funding opportunities• profiles of selected programmes• call calendar excerpt

• Q&A

Page 8: Exeq BioForum 2012 presentation

8Public funding for R&D&I

motto

„People say you have to rob your first 1 million, I got mine from a public grant”

- Mateusz Flis, founder of Ives System

Page 9: Exeq BioForum 2012 presentation

9Public funding for R&D&I

overview• 7th Framework Programme --> Horizon 2020• Eureka• Eurostars• ERASME• EEA Grants• Israeli Industrial bilateral R&D Cooperation

Framework

Page 10: Exeq BioForum 2012 presentation

10

Public funding for R&D&I

7th Framework Programme

Planned for the years 2007-2013

--> Horizon 2020 (in 587 days)

Total budget of € 50 billion

•based on calls for proposals •peer reviewed•highly competitive•medium to large cross-EU consortia•considerable budgets (EUR ~2-20M)

Page 11: Exeq BioForum 2012 presentation

11

Public funding for R&D&I

who can apply?

open to a wide range of organisations, including:

• research groups at universities or research institutes

• small or medium-sized enterprises (SMEs)

• public or governmental administration (local, regional or national)

• international organisations

• civil society organisations

from:

EU member countries & associate countries (EEA, candidate countries, Israel, Switzerland)

Page 12: Exeq BioForum 2012 presentation

12

Public funding for R&D&I

FP Structure5 major building blocks: • Ideas• People• Capacities• Nuclear Research• Cooperation (the core of FP7, representing two thirds

of the overall budget)

Ten thematic areas including: • HEALTH• FOOD, AGRICULTURE AND FISHERIES,

BIOTECHNOLOGY

Page 13: Exeq BioForum 2012 presentation

13

Public funding for R&D&I

basic FP rules

Participation Duration Max budget Funding rate

Average: 5 - 16 36 monthsOn average: EU contribution €2M

R&D activities up to 75%Demonstration 50%Other up to 100%

Page 14: Exeq BioForum 2012 presentation

14

Public funding for R&D&I

calls• Health - 20 closed calls• Food, Agriculture and Fisheries, and Biotechnology –

21 closed calls

• Work Programmes for 2013 expected in mid-July 2012

http://ec.europa.eu/research/participants/portal/page/cooperation

• Orientation paper now online!, via the above address

Page 15: Exeq BioForum 2012 presentation

15

Public funding for R&D&I

topics in the orientation paper

BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

• 1.1 High-throughput research• 1.2 Detection, diagnosis and monitoring• 1.3 Suitability, safety, efficacy of therapies• 1.4 Innovative therapeutic approaches and interventionsTRANSLATING RESEARCH FOR HUMAN HEALTH• 2.1 Integrating biological data and processes: large-scale data

gathering, systems biology• 2.2 Research on the brain and related diseases, human development

and ageing• 2.3 Translational research in major infectious diseases: to confront

major threats to public health• 2.3.1 Anti-microbial drug resistance

2.3.2 HIV/AIDS, malaria and tuberculosis2.3.3 Potentially new and re-emerging epidemics2.3.4 Neglected infectious diseases

Page 16: Exeq BioForum 2012 presentation

16

Public funding for R&D&I

topics in the orientation paper

• 2.4 Translational research in other major diseases2.4.1 Cancer2.4.2 Cardiovascular diseases2.4.3 Diabetes and obesity2.4.4 Rare diseases2.4.5 Other chronic diseases

• 3.1 Translating the results of clinical research outcome into clinical practice

• 3.2 Quality, efficiency and solidarity of healthcare systems

• 3.3 Health promotion and prevention

Page 17: Exeq BioForum 2012 presentation

17

Public funding for R&D&I

EUREKA

• International network of 40 partners

• 200 projects yearly

• Any technological area

MAIN RULES:

• At least 2 partners from 2 different member countries

• Funded under national funding schemes

• Market driven

Page 18: Exeq BioForum 2012 presentation

18

Public funding for R&D&I

EUREKAFunding schemes:

(1) individual projects

Open call (around 490 running projects)

(2) umbrellas

Thematic networks

EUROAGRI FOOD CHAIN (2009-2013)

(3) Clusters

Long-term, strategically significant industry initiatives

ACQUEAU (2010-2015)

(4) EUROSTARS

Page 19: Exeq BioForum 2012 presentation

19

Public funding for R&D&I

EUREKA

Participation Duration Max budget Funding rate

At least 2 partners from 2 different member countries

Not specified € 1,6 Mon average

According to national rules

Page 20: Exeq BioForum 2012 presentation

20

Public funding for R&D&I

EUROSTARS

• Funding industrial research carried out by SME’s

• €400M of budget

• 2 calls of proposals yearly

• Any technological area

• New product, process or service

• Market perspective

• Leader: R&D-performing SME

• At least 50% of R&D work done by SMEs

• Funded under national schemes

Właściciel
pomijam wszystkie informacje związane z procedurą aplikowania, bo są mniej istotne niż inne informacje o programach
Page 21: Exeq BioForum 2012 presentation

21

Public funding for R&D&I

EUROSTARS

Participation Duration Budget Funding rate Upcoming call

At least 2 partners from 2 different member countries

Up to 36 months

Not specified According to national rules

Autumn 2012

On average:3 to 4 partners

On average:29 months

On average:€1,4 M

-- --

Page 22: Exeq BioForum 2012 presentation

22

Public funding for R&D&I

EUROSTARSExamples:

Eurostars E!4258 ISTAR

Injection System for Transderm Administration of dRugs

Budget: 3580000 €

Led by: CROSSJECT Medical Technology (France)

E! 4731 Arrayvolution

A revolution in flexible cost-effective DNA and high density microarray production

Budget: 1443500 €

Led by: FlexGen (The Netherlands)

Page 23: Exeq BioForum 2012 presentation

23

Public funding for R&D&I

EEA Grants• „EEA structural funds”• Key areas of support : environmental protection, climate

change, research and scholarships, civil society, health and children, gender equality, justice and cultural heritage.

• 2009-14: €1.79 billion (Norway: 97%)

• Available for NGOs, research and academic institutions, and the public and private sectors in the 12 newest EU member states, Greece, Portugal and Spain.

• The funding backs programmes and projects in priority areas agreed with each country.

Page 24: Exeq BioForum 2012 presentation

24

Public funding for R&D&I

EEA Grants

http://www.eeagrants.org

Page 25: Exeq BioForum 2012 presentation

25

Public funding for R&D&I

Israeli bilateral coop.Sellected calls:Czech Republic-Israel Industrial R&D Cooperation Framework (Dec2012?)Russia-Israel Call for Proposals (10 Sept)

Countries involved:Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Lithuania, Poland, Romania, Russia, Spain, Sweden, Switzerland, Turkey, UK

Page 26: Exeq BioForum 2012 presentation

26

Public funding for R&D&I

calls calendar• 7th Framework Programme --> 2013 (to be published

mid-July)• Eureka - ongoing• Eurostars – Autumn 2012• ERASME – 28th September 2012• Celtic – 15th October 2012• Israeli Industrial bilateral R&D Cooperation

Framework – September with Russia, Poland and Czech Republic

If you want to stay tuned subscribe to our newsletter at: www.exeq.eu

Page 27: Exeq BioForum 2012 presentation

27

Public funding for R&D&I

food 4 thought• keep focus on your idea• be market oriented• team up with academics• build up your research project portfolio• money is not all you can get• submit often, never give up

Page 28: Exeq BioForum 2012 presentation

28

Public funding for R&D&I

questions?

Page 29: Exeq BioForum 2012 presentation

29

Public funding for R&D&I

how we can help…• Research concept• State of the art analysis• Market research• Concept adaptation• Program search• Project parter serach• Standard consortium agreement• Project budgeting• Project plan and tasks• Project application form filling out and submission

Page 30: Exeq BioForum 2012 presentation

30

Public funding for R&D&I

…• Project financial reporting• Project merit reporting• Project merit audit• Project formal audit• Project reporting training• R&D projects funding possibilities training• Project application preparation training

Page 31: Exeq BioForum 2012 presentation

31

Public funding for R&D&I

contact me!Exeq (a brand of Disruptive Concepts Sp. z o.o.)ul. Willowa 2 lok. 1, 00-790 Warsaw, Poland

E-mail: [email protected]

@exeq_eu

facebook.com/EXEQ.EU

linkedin.com/companies/exeq

Find us on: www.exeq.eu